[Novel combinations of irinotecan with molecular-targeted drugs in the treatment of colorectal carcinoma].
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000068818:Cetuximab; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D003545:Cysteine / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077146:Irinotecan; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D003545:Cysteine; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
Nuove combinazioni di irinotecan con i farmaci "molecular targeted" nel trattamento del carcinoma del colon-retto.